Open-label, non-comparative study of combination use of ONO-4538 and ONO-7703 in patients with advanced or metastatic solid tumors

Trial Profile

Open-label, non-comparative study of combination use of ONO-4538 and ONO-7703 in patients with advanced or metastatic solid tumors

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Binimetinib (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 23 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top